For the quarter ending 2026-03-31, MMSI had $41,700K increase in cash & cash equivalents over the period. $24,672K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 381,877 | - | - | - |
| Cost of sales standard | 147,017 | - | - | - |
| Cost of sales other | 50,063 | - | - | - |
| Selling and marketing expenses | 73,957 | - | - | - |
| General and administrative expenses | 44,253 | - | - | - |
| Research and development expenses | 22,609 | - | - | - |
| Other operating expenses | -179 | - | - | - |
| Other (income) expense - net | 9,389 | - | - | - |
| Income tax expense | 12,551 | - | - | - |
| Net income | 40,995 | 38,006 | 27,755 | 62,728 |
| Depreciation and amortization | 30,496 | 31,539 | 31,316 | 60,313 |
| Gain on disposition of business | 12,502 | 0 | 0 | 249 |
| Share of equity investee loss | -531 | - | - | - |
| Loss on sale or abandonment of property and equipment | -67 | -1,756 | -231 | -315 |
| Write-off of certain intangible assets and other long-term assets | 137 | 161 | 70 | 82 |
| Amortization of right-of-use operating lease assets | 2,854 | 2,788 | 2,927 | 5,766 |
| Fair value adjustments related to contingent consideration liabilities | -179 | -214 | 32 | 1,166 |
| Amortization of deferred credits | 26 | 26 | 25 | 52 |
| Amortization and write-off of long-term debt issuance costs | - | 1,414 | 1,414 | 2,828 |
| Deferred income taxes | - | 5,214 | - | - |
| Amortizationof long-term debt issuance costs | 1,414 | - | - | - |
| Stock-based compensation expense | 8,961 | 9,897 | 13,612 | 19,951 |
| Trade receivables | 3,577 | -6,315 | 6,346 | 7,310 |
| Other receivables | -2,067 | -2,252 | 701 | -2,817 |
| Inventories | 22,655 | 6,529 | 3,353 | 11,720 |
| Prepaid expenses and other current assets | -1,886 | -518 | 463 | 2,575 |
| Prepaid income taxes | - | 1,612 | - | - |
| Income tax refund receivables | -188 | -386 | -3,513 | 3,653 |
| Other assets | 723 | -132 | 358 | 1,471 |
| Trade payables | 4,493 | -2,417 | -269 | 3,697 |
| Accrued expenses | -33,269 | 9,413 | 7,589 | -2,740 |
| Income taxes payable | 7,459 | 1,745 | 1,948 | 1,537 |
| Liabilities related to unrecognized tax benefits | - | 80 | - | - |
| Deferred compensation payable | -169 | 459 | -2,717 | 603 |
| Operating lease liabilities | -2,766 | -2,589 | -2,653 | -5,925 |
| Other long-term obligations | 14,999 | -178 | 1,460 | -2,229 |
| Total adjustments | -314 | 60,504 | 47,227 | 61,151 |
| Net cash, cash equivalents, and restricted cash provided by operating activities | 40,681 | 98,510 | 74,982 | 123,879 |
| Proceeds from the sale of property and equipment | - | - | 4 | 45 |
| Proceeds from disposition of business | - | - | 0 | 249 |
| Property and equipment | 16,009 | 24,464 | 22,440 | 34,812 |
| Proceeds from asset and business dispositions | - | 303 | - | - |
| Cash paid for notes receivable and other investments | - | 3,148 | 319 | 14,617 |
| Intangible assets | 757 | 793 | 1,031 | 1,296 |
| Proceeds from asset and business dispositions | 25,500 | - | - | - |
| Cash paid in acquisitions, net of cash acquired | 1,000 | 21,935 | 279 | 122,555 |
| Net cash, cash equivalents, and restricted cash provided by (used in) investing activities | 7,734 | -50,335 | -24,065 | -172,986 |
| Proceeds from issuance of common stock | 2,775 | 6,034 | 2,165 | 20,014 |
| Contingent payments related to acquisitions | 2,142 | 40 | 78 | 2,567 |
| Payment of taxes related to an exchange of common stock | 6,922 | 932 | 2,452 | 6,145 |
| Net cash, cash equivalents, and restricted cash (used in) provided by financing activities | -6,289 | 5,062 | -365 | 11,302 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | -426 | 751 | 94 | 2,953 |
| Net increase in cash, cash equivalents and restricted cash | 41,700 | 53,988 | 50,646 | -34,852 |
| Beginning of period | 448,549 | -15,794 | 378,767 | - |
| End of period | 490,249 | 53,988 | 394,561 | - |
MERIT MEDICAL SYSTEMS INC (MMSI)
MERIT MEDICAL SYSTEMS INC (MMSI)